Condition
Mucosal Melanoma of the Head and Neck
Total Trials
2
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Withdrawn1
Recruiting1
Clinical Trials (2)
Showing 2 of 2 trials
NCT04318717Phase 2RecruitingPrimary
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
NCT03220009Phase 2Withdrawn
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
Showing all 2 trials